Endostatin enhances radioresponse in breast cancer cells via alteration of substance P levels

Oncology Letters

Volumn 2, Issue 5, 2011, Pages 879-886

  Aydemir, Esra Arslan ^a,c   Oz, Ece Simsek ^a,c   Korcum, Aylin Fidan ^b   Fiskin, Kayahan ^a  

^a Departments of Biology   (Turkey)

^b MKU University School of Medicine   (Turkey)

^c AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Endostatin; Radiotherapy; Substance P

Indexed keywords

RECOMBINANT ENDOSTATIN; SUBSTANCE P;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL LYSATE; CELL PROLIFERATION; CONTROLLED STUDY; CULTURE MEDIUM; IMMUNOPRECIPITATION; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TREATMENT RESPONSE; WESTERN BLOTTING;

EID: 79960328826     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.335     Document Type: Article

References (33)

1. Milani M and Harris AL: Targeting tumor hypoxia in breast cancer. Eur J Cancer 44: 2766-2773, 2008.
2. Chua B, Olivotto IA, Weir L, Kwan W, Truong P and Ragaz J: Increased use of adjuvant regional radiotherapy for node-positive breast cancer in British Columbia. Breast J 10: 38-44, 2004.
3. Chan LW and Camphausen K: Angiogenic tumor markers, antiangiogenic agents and radiation therapy. Expert Rev Anticancer Ther 3: 357-366, 2003.
4. Zhuang HQ and Yuan ZY: Process in the mechanisms of endo-statin combined with radiotherapy. Cancer Lett 282: 9-13, 2009.
5. Verhoef C, de Wilt JHW and Verheul HMW: Angiogenesis inhibitors: perspectives for medical, surgical and radiation oncology. Curr Pharma Design 12: 2623-2630, 2006.
6. Itasaka S, Komaki R, Herbst RS, Shibuya K, Shintani T, Hunter NR, Onn A, Bucana CD, Milas L, Ang KK and O'Reilly MS: Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys 67: 870-878, 2007.
7. Esteban F, Munoz M, Gonzalez-Moles MA and Rosso M: A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev 25: 137-145, 2006.
8. Korcum AF, Sanlioglu S, Aksu G, Tuncel N and Erin N: Radiotherapy-induced decreases in Substance P levels may potentiate melanoma growth. Mol Med Rep 2: 319-326, 2009.
9. Esteban F, Gonzalez-Moles MA, Castro D, Martin-Jaen MDM, Redondo M, Ruiz-Avila I and Muñoz M: Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. Histopathology 54: 258-260, 2009.
10. Erin N, Wang N, Xin P, Bui V, Weisz J, Barkan GA, Zhao W, Shearer D and Clawson GA: Altered gene expression in breast cancer liver metastases. Int J Cancer 124: 1503-1516, 2009.
11. Erin N and Clawson GA: Parameters affecting substance P measurement in heart, lung, and skin. Bio Techniques 37: 232-239, 2004.
12. Deeppreet S, Deval DJ, Meera H, Qian J, Gascón P, Maloof PB, Mosenthal A and Rameshwar P: Increased expression of prepro-tachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis. Proc Natl Acad Sci USA 97: 388-393, 2000.
13. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
14. Zatterstrom UK, Felbor U, Fukai N and Olsen BR: Collagen XVIII/Endostatin structure and functional role in angiogenesis. Cell Struct Funct 25: 97-101, 2000.
15. Kranenburg O, Kroon-Batenburg LMJ, Reijerkerk A, Wu YP, Voest EE and Gebbink MFBG: Recombinant endostatin forms amyloid fibrils that bind and are cytotoxic to murine neuroblastoma cells in vitro. Febs Lett 539: 149-155, 2003.
16. Folkman J: Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res 312: 594-607, 2006.
17. Sjin RMTT, Naspinski J, Birsner AE, Li C, Chan R, Lo KM, Gillies S, Zurakowski D, Folkman J, Samulski J and Javaherian K: Endostatin therapy reveals a U-shaped curve for antitumor activity. Cancer Gene Ther 13: 619-627, 2006.
18. Dhanabal M, Ramchandran R, Waterman MJF, Lu H, Knebelmann B, Segal M and Sukhatme VP: Endostatin induces endothelial cell apoptosis. J Biol Chem 274: 11721-11726, 1999.
19. Dhanabal M, Volk R, Ramchandran R, Simons M and Sukhatme VP: Cloning, expression, and in vitro activity of human endostatin. Biochem Bioph Res Commun 258: 345-352, 1999.
20. Yoon SS, Eto H, Lin CM, Nakamura H, Pawlik TM, Song SU and Tanabe KK: Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 59: 6251-6256, 1999.
21. Jin X, Bookstein R, Wills K, Avanzini J, Tsai V, LaFace D, Terracina G, Shi B and Nielsen LL: Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. Cancer Gene Ther 8: 982-989, 2001.
22. Ye C, Feng C, Wang S, Liu X, Lin Y and Li M: Antiangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma. Endocrinology 143: 3522-3528, 2002.
23. Te Velde EA, Reijerkerk A, Brandsma D, Vogten JM, Wu Y, Kranenburg O, Voest EE, Gebbink M and Borel Rinkes IHM: Early endostatin treatment inhibits metastatic seeding of murine colorectal cancer cells in the liver and their adhesion to endothelial cells. Brit J Cancer 92: 729-735, 2005.
24. Dkhissi F, Lu H, Soria C, Opolon P, Griscelli F, Liu H, Khattar P, Mishal Z, Perricaudet M and Li H: Endostatin exhibits a direct antitumor effect in addition to its antiangiogenic activity in colon cancer cells. Hum Gene Ther 14: 997-1008, 2003.
25. Hajitou A, Grignet-Debrus C, Devy L, Berndt S, Blacher S, Deroanne CF, Bajou K, Fong T, Chiang Y, Foidart JM and Noël A: The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. Faseb J 16: 1802, 2002.
26. Hanai J, Gloy J, Karumanchi SA, Kale S, Tang J, Hu G, Chan B, Ramchandran R, Jha V, Sukhatme VP and Sokol S: Endostatin is potential inhibitor of Wnt signaling. J Cell Biol 158: 529-539, 2002.
27. Teicher BA: A systems approach to cancer therapy. Cancer Metastasis Rev 15: 247-272, 1996.
28. Zips D, Krause M, Hessel F, Westphal J, Brüchner K, Eicheler W, Dörfler A, Grenman R, Petersen C, Haberey M and Baumann M: Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res 23: 3869-3876, 2003.
29. Teicher BA, Dupuis N, Kusomoto T, Robinson MF, Liu F, Menon K and Coleman CN: Anti-angiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Investig 2: 269-276, 1994.
30. Hanna NN, Seetharam S, Mauceri HJ, Beckett MA, Jaskowiak NT, Salloum RM, Hari D, Dhanabal M, Ramchandran R, Kalluri R, Sukhatme VP, Kufe DW and Weichselbaum RR: Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J 6: 287-293, 2000.
31. Vala IS, Martins LR, Imaizumi N, Nunes RJ, Rino J, Kuonen F, Carvalho LM, Rüegg C, Grillo IM, Barata JT, Mareel M and Santos SCR: Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS One 5: e11222, 2010.
32. Salo P, Bray R, Seerattan R, Reno C, McDougall J and Hart DA: Neuropeptides regulate expression of matrix molecule, growth factor and inflammatory mediator mRNA in explants of normal and healing medial colleteral ligament. Regul Peptides 142: 1-6, 2007.
33. Aalto Y, Forsgren S, Kjörell U, Bergh J, Franzén L and Henriksson R: Enhanced expression of neuropeptides in human breast cancer cell lines following irradiation. Peptides 19: 231-239, 1998.